Published in AIDS Weekly, August 8th, 2005
"We evaluated the safety and efficacy of peginterferon alpha-2a (pegIFN alpha-2a), with or without ribavirin, in 154 hepatitis C virus/human immunodeficiency virus (HCV/HIV) coinfected patients. All received pegIFN alpha-2a (180 mcg/week) for 12 weeks, with those achieving an early virologic response (EVR) continued on monotherapy through week 48," researchers in the United States report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.